Research Highlights

Since its inception, the Vancouver Prostate Centre’s research activities have led to valuable new insights, treatments, and intellectual property:

  • We were instrumental in establishing the use of Intermittent Androgen Ablation Therapy as a standard treatment modality for prostate cancer
  • In 2015, the Centre developed a potential new therapeutic that is designed to outsmart cancer and inhibit tumour growth by disabling the androgen receptor where it binds to a specific part of the DNA that is not prone to mutation, opening the possibility of designing drugs that could be effective for a long time
    • The drug candidate was developed using new CADD (computer aided drug design), a computer technology that evaluates a database of millions of different molecules to identify a handful which may work well as possible treatments
  • My Precision Oncology Program (MyPOP), made possible by new infrastructural investment from the Canadian Foundation for Innovation and a generous donation by a private donor, allows for the routine linking of genomic sequencing data with real-time clinical decision making
  • Our annual knowledge output averages 80 peer-reviewed publications and 75 presentations at conferences
  • Since 2008, our Centre has been awarded over $80 million in peer-reviewed research grants from regional, national and international agencies
  • Since 2008 we have initiated 109 new Clinical Trials enrolling 1,721 patients
  • We have a strong record of recruitment of senior staff and faculty promotions
  • The Centre currently had 44 post-doctoral fellows, 31 Ph.D. students and 21 Masters students
  • Since 2008 we have negotiated 52 new contract research agreements with pharmaceutical and biotech companies including Pfizer, Takeda and AstraZeneca
  • Intellectual Property Activities since 2008 include
    •  259 patent filed/issued
    •  9 Licensing Agreements of IP with Industry (8 drug, 1 Biomarker)
  • Discoveries at our Centre have created four biotech companies:
    • OncoGeneX
      • OGX-011 : in advanced Phase III studies
      • OGX-427 : in multiple Phase II studies
    • Aquinox 
      • shp inhibitors, in Phase II studies
    • Andronex
      • novel AR ligands
    • Sitka Biopharma
      • Formulations of Paclitaxel for bladder cancer

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Terry Fox Run, Sunday September 17

The Terry Fox Walk/Run for Prostate Cancer takes place on Sunday September 17. The Vancouver Prostate Centre team page is open for those who wish to join or donate.

Employment

Work at the Vancouver Prostate Centre

Monday, January 30, 2017

Dr. Amina Zoubeidi leads identification of gene linked to growth of aggressive neuroendocrine prostate cancer (NEPC)

DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.